Compare iShares MSCI South Korea ETF (EWY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI South Korea ETF trades at $163.96, while Regeneron Pharmaceuticals Inc trades at $677.44 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWY | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $812.27 |
52-Week Low | $70.65 | $542.52 |
Market Cap | — | $69.66B |
Enterprise Value | — | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.
The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
